FARMAMONDO INNOVATIVE THERAPIES
We are a fast-growing Swiss based pharmaceutical group providing access to specialty medicines to doctors and hospitals, through a unique service and geographical footprint, in more than 80 markets.
We provide oncologists, paediatric oncologists and rare disease specialists with Managed Access Programs (MAPs) around the globe, wherever innovative treatments are not commercially available.
KEY ACTIVE INDICATIONS
|Neuroblastoma (NB)||EUSA Pharma||Dinutuximab beta / QARZIBA®|
|Acute Lymphoblastic Leukaemia (ALL)||Gennova Bio||Pegaspargase / HAMSYL®|
|Neurotrophic Keratitis (NK)||Dompé||Cenegermin / OXERVATETM|
|Duchenne Muscular Dystrophy (DMD)||Sarepta||Eteplirsen / EXONDYS 51®
Golodirsen / VYONDYS 53®
Casimersen / AMONDYS 45®
|Paroxysmal Nocturnal Hemoglobinuria (PNH)||Generium||Eculizumab / ELIZARIA®|
|Atypical Hemolytic Uremic Syndrome (aHUS)||Generium||Eculizumab / ELIZARIA®|
We have active MAPs in Russia, Commonwealth of Independent States, India, Asia, Latin America, Middle East and Africa. Note that the availability of MAPs is decided country by country, based on strict criteria such as agreements with the manufacturer, IP rights, and might not be available across each region.
MANAGED ACCESS PROGRAMS (MAPS)
Our Managed Access Programs (often called Named Patient Programs) service gives access to the Physicians and Hospitals the possibility to treat patients with innovative FDA or EMA approved medicines which are not commercially available in their home countries. To cover these unmet medical needs, most countries have put in place specific pathways to give access to and finance these unapproved but life-saving treatments for eligible patients.
QUALITY & COMPLIANCE